Positions

Overview

  • I am a pediatric oncologist with a focus on solid tumors and end-of-life care research. I am originally from Iowa, went to Carleton College in Minnesota for undergraduate before heading to Stanford for my medical training. I joined the UAB faculty July 2018. I live in Homewood with my son and husband and enjoy running, reading, hiking, and spending time with my little guy.
  • Research Overview

  • My research focuses on disparities in end-of-life care for children - from what the disparities are to what constitutes high quality end-of-life care to how we provide higher quality end-of-life care.
  • Investigator On

  • NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)  awarded by SPECTRUM HEALTH 2017 - 2022
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma  awarded by SPECTRUM HEALTH 2017 - 2022
  • APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION  awarded by CHILDREN'S ONCOLOGY GROUP 2017 - 2022
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • Intensity of End-of-Life Care of Children, Adolescents, and Young Adults with Hematologic Malignancies: Rates, Disparities, and Appropriateness  awarded by Leukemia and Lymphoma Society 2018 - 2021
  • Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2021
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • End-of-Life Care of Children with Cancer: Variation and Stakeholder Priorities  awarded by Alex's Lemonade Stand 2018 - 2020
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2020
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Full Name

  • Emily Johnston